Ortega RAT, García RMT, Lacy NRM

Language: Spanish
References: 23
Page: 270-279
PDF size: 178.64 Kb.

ABSTRACT

Vitiligo is an acquired depigmenting disorder characterized by the progressive loss of melanocytes in the epidermis. It has an unpredictable but often progressive course. Treatment is based on achieving repigmentation through the activation of melanocytes of the hair follicles. We can observe different modalities and success rates and also spontaneous repigmentation. Even though it is a dermatological disease with low morbidity, it has a negative psychological impact on the patient´s quality of life.

REFERENCES

1. Ongenae K, Mollet I, Naeyaert JM. “Origin, clinical presentation, and diagnosis of hypomelanotic skin disorders”. Dermatol Clin 2007; 25: 363-371.

2. Taieb A, Picardo M. “Vitiligo”. N Engl J Med 2009; 360(2): 160-169.

3. Plensdorf S, Martinez J. “Common pigmentation disorders”. Am Fam Physician 2009; 79(2): 109-116.

4. Matz H, Tur E. “Vitiligo”. Curr Probl Dermatol 2007; 35: 78-102.

5. Wolff K, Johnson RA, Suurmond D. “Pigmentary disorders”. En Wolff K, Johnson RA, Suurmond D, Fitzpatrick’s Color Atlas & Synopsis of Clinical Dermatology. 5a. ed. EUA. McGraw-Hill, 2005, 591-621.

6. Krutmann J, Hönigsmann H, Elmets C et al. “Dermatological phototherapy and photodiagnostic methods”. Springer, 2001: 135-156.

7. Le Poole IC, Wankowicz-Kalinska A, van den Wijngaard RM et al. “Autoimmune aspects of depigmentation in vitiligo”. J Investig Dermatol Symp Proc 2004; 9(1): 68-72.

8. Van den Boorn JG, Konijnenberg D, Dellemijn TA et al. “Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients”. J Invest Dermatol 2009 feb 26.

9. Falabella R, Barona MI. “Update on skin repigmentation therapies in vitiligo”. Pigment Cell Melanoma Res 2008; 22: 42-65.

10. Habif T. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 4a. ed. Chile. Mosby, 2004, 684-689.

11. Kovacs SO. “Vitiligo”. J Am Acad Dermatol 1998; 38(5 pt. 1): 647-666.

12. Hercogova J, Buggiani G, Prignano F, Lotti T. “Rational approach to the treatment of vitiligo and other hypomelanoses”. Dermatol Clin 2007; 25: 383-392.

13. El-Mofty M, Mostafa W, Youssef R et al. “Ultraviolet A in vitiligo”. Photodermatol Photoinmunol Photomed 2006; 22: 214-216.

14. Ortonne JP, Passeron T. “Melanin pigmentary disorders: Treatment update”. Dermatol Clin 2005; 23: 209-226.

15. Kishan Kumar YH, Rao GR, Gopal KV et al. “Evaluation of narrowband UVB phototherapy in 150 patients with vitiligo”. Indian J Dermatol Venereol Leprol 2009; 75(2): 162-166.

16. Pericivalle S, Piccino R, Caccialanza M et al. “Narrowband UVB phototherapy in vitiligo: Evaluation of results in 53 patients”. G Ital Dermatol Venereol 2008; 143(1): 9-14.

17. Hadi SM, Spencer JM. “Vitiligo”. En Mark G. Lebwohl, WR Hey - mann, J Berth-Jones. Treatment of Skin Disease. Comprehensive Therapeutic Strategies. Filadelfia, 2006, 683-687.

18. Lotti T, Prignano F, Buggiani G. “New and experimental treatments of vitiligo and other hypomelanoses”. Dermatol Clin 2007; 25: 393-400.

19. Lotti T, Buggiani G, Troiano M et al. “Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects”. Dermatol Ther 2008; 21(1 supl.): S20-S26. 20.Choi CW, Chang SE, Bak H et al. Topical immunomodulators are effective for treatment of vitiligo”. J Dermatol 2008; 35(8): 503-507.

20. Kapoor R, Phiske MM, Jerajani HR. “Evaluation for safety and efficacy of topical prostaglandin E2 in treatment of vitiligo”. Br J Dermatol 2009; 160(4): 861-863.

21. Grandhe NP, Dogra S, Kumar B. “Spontaneous repigmentation of vi - tiligo in an untreated HIV-positive patient”. JEADV 2006; 20: 214-238.

22. Malakar S, Lahiri K. “Spontaneous repigmentation in vitiligo: Why it is important”. Int J Dermatol 2006; 45: 478-479.

23. Han H, Yu YY, Wang YH. “Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors”. J Am Acad Dermatol 2008; 59(supl. 5): S80-S83.